Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BLUE Stock Forecast 2026-2027
$4.97
Current Price
$48.67M
Market Cap
Buy 1
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to BLUE Price Targets
+61.0%
To High Target of $8.00
+61.0%
To Median Target of $8.00
+61.0%
To Low Target of $8.00
BLUE Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
+6.4%
1 Year Change
0.0%
Year-to-Date Change
-82.6%
From 52W High of $28.60
+55.3%
From 52W Low of $3.20
📊 TOP ANALYST CALLS
Did BLUE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Bluebird Bio is one of their latest high-conviction picks.
Latest BLUE Stock Price Targets & Analyst Predictions
Based on our analysis of 24 Wall Street analysts, BLUE has a neutral consensus with a median price target of $8.00 (ranging from $8.00 to $8.00). The overall analyst rating is Buy (7.0/10). Currently trading at $4.97, the median forecast implies a 61.0% upside. This outlook is supported by 1 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Gena Wang at Barclays, projecting a 61.0% upside. Conversely, the most conservative target is provided by Gena Wang at Barclays, suggesting a 61.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BLUE Analyst Ratings
1
Buy
1
Hold
0
Sell
BLUE Price Target Range
Low
$8.00
Average
$8.00
High
$8.00
Current: $4.97
Latest BLUE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BLUE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 31, 2025 | Barclays | Gena Wang | Overweight | Maintains | $8.00 |
| Feb 24, 2025 | Wells Fargo | Yanan Zhu | Equal-Weight | Maintains | $5.00 |
| Feb 24, 2025 | JP Morgan | Eric Joseph | Neutral | Upgrade | $N/A |
| Dec 31, 2024 | Barclays | Gena Wang | Overweight | Maintains | $40.00 |
| Nov 15, 2024 | RBC Capital | Luca Issi | Sector Perform | Reiterates | $4.00 |
| Nov 15, 2024 | Barclays | Gena Wang | Overweight | Maintains | $2.00 |
| Nov 15, 2024 | B of A Securities | Jason Gerberry | Neutral | Downgrade | $0.50 |
| Sep 25, 2024 | Wells Fargo | Yanan Zhu | Equal-Weight | Maintains | $2.00 |
| Sep 16, 2024 | Cantor Fitzgerald | Eric Schmidt | Neutral | Reiterates | $N/A |
| Aug 15, 2024 | B of A Securities | Jason Gerberry | Buy | Maintains | $3.00 |
| Aug 15, 2024 | JP Morgan | Eric Joseph | Neutral | Downgrade | $N/A |
| Aug 15, 2024 | Barclays | Gena Wang | Overweight | Maintains | $4.00 |
| Aug 15, 2024 | RBC Capital | Luca Issi | Sector Perform | Reiterates | $4.00 |
| Aug 15, 2024 | Baird | Jack Allen | Outperform | Maintains | $6.00 |
| Mar 27, 2024 | RBC Capital | Luca Issi | Sector Perform | Reiterates | $6.00 |
| Mar 27, 2024 | Wells Fargo | Yanan Zhu | Equal-Weight | Maintains | $3.00 |
| Mar 19, 2024 | Wedbush | David Nierengarten | Neutral | Maintains | $1.68 |
| Mar 5, 2024 | HSBC | Morten Herholdt | Reduce | Maintains | $1.02 |
| Dec 21, 2023 | B of A Securities | Jason Gerberry | Buy | Maintains | $5.00 |
| Dec 15, 2023 | Wells Fargo | Yanan Zhu | Equal-Weight | Maintains | $5.00 |
bluebird bio, Inc. (BLUE) Competitors
The following stocks are similar to Bluebird Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
bluebird bio, Inc. (BLUE) Financial Data
bluebird bio, Inc. has a market capitalization of $48.67M with a P/E ratio of -0.2x. The company generates $103.95M in trailing twelve-month revenue with a -192.4% profit margin.
Revenue growth is +108.4% quarter-over-quarter, while maintaining an operating margin of -55.6% and return on equity of -546.5%.
Valuation Metrics
Market Cap
$48.67M
Enterprise Value
$186.92M
P/E Ratio
-0.2x
PEG Ratio
-7.6x
Price/Sales
0.5x
Growth & Margins
Revenue Growth (YoY)
+108.4%
Gross Margin
+68.4%
Operating Margin
-55.6%
Net Margin
-192.4%
EPS Growth
+108.4%
Financial Health
Cash/Price Ratio
+161.8%
Current Ratio
0.6x
Debt/Equity
-3.8x
ROE
-546.5%
ROA
-28.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
bluebird bio, Inc. (BLUE) Business Model
About bluebird bio, Inc.
What They Do
Develops innovative gene therapies for genetic diseases.
Business Model
Bluebird Bio generates revenue through the research, development, and commercialization of its gene therapies aimed at severe genetic diseases and cancers. By utilizing advanced lentiviral-based techniques, the company offers transformative treatments that can lead to long-term patient benefits, thus creating a strong market demand for its innovative solutions.
Additional Information
Founded in 1992 and based in Cambridge, Massachusetts, Bluebird Bio is at the forefront of genetic medicine, significantly impacting healthcare and pharmaceutical sectors. Its pioneering approach in gene therapy positions the company as a key player in the evolving landscape of precision medicine.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
248
CEO
Mr. Andrew Obenshain
Country
United States
IPO Year
2013
Website
www.bluebirdbio.combluebird bio, Inc. (BLUE) Latest News & Analysis
Latest News
Quick Summary
bluebird bio, Inc. has rebranded as Genetix Biotherapeutics Inc., focusing on genetic therapies with a strengthened financial and operational position under new CEO David Meek.
Why It Matters
The rebranding to Genetix Biotherapeutics and strengthened financial position may enhance investor confidence and attract interest in its genetic therapies, potentially driving stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
bluebird bio has appointed Brian Riley as President and CTO, Joanne Lager, MD as CMO, and Adrian Chaisson as Chief of Staff, enhancing its management team in gene therapy.
Why It Matters
Leadership changes at bluebird bio could signal a strategic shift, impacting innovation and operational efficiency, which may affect the company's stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
bluebird bio has completed its sale to Carlyle and SK Capital, resulting in its common stock ceasing to trade and delisting from public markets.
Why It Matters
bluebird bio's delisting indicates a shift to private ownership, potentially altering its growth trajectory and access to capital, impacting future investor interest and valuations in biotech.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Carlyle, SK Capital, and Beacon Parent Holdings have launched a tender offer to acquire bluebird bio for $3.00 per share and a contingent value right potentially worth $6.84.
Why It Matters
Carlyle's tender offer for bluebird bio at $3 per share indicates potential volatility in bluebird's stock and reflects market confidence in its future prospects tied to the CVR.
Source: Business Wire
Market Sentiment:
Neutral
bluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK Capital
10 months ago
Quick Summary
bluebird bio (NASDAQ: BLUE) urges stockholders to tender shares in the Carlyle and SK Capital offer by May 29, 2025, noting potential early cutoffs for broker-held shares.
Why It Matters
The tender offer by Carlyle and SK Capital may influence bluebird bio's stock price and investor decisions, impacting liquidity and potential future ownership structure.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Carlyle and SK Capital will acquire all outstanding shares of bluebird bio. Updated instructions for stockholders to tender shares have been issued.
Why It Matters
The amendment of the acquisition agreement may signal changes in valuation or strategy, impacting shareholder sentiment and stock prices for Carlyle and bluebird bio.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About BLUE Stock
What is bluebird bio, Inc.'s (BLUE) stock forecast for 2026?
Based on our analysis of 24 Wall Street analysts, bluebird bio, Inc. (BLUE) has a median price target of $8.00. The highest price target is $8.00 and the lowest is $8.00.
Is BLUE stock a good investment in 2026?
According to current analyst ratings, BLUE has 1 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.97. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BLUE stock?
Wall Street analysts predict BLUE stock could reach $8.00 in the next 12 months. This represents a 61.0% increase from the current price of $4.97. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is bluebird bio, Inc.'s business model?
Bluebird Bio generates revenue through the research, development, and commercialization of its gene therapies aimed at severe genetic diseases and cancers. By utilizing advanced lentiviral-based techniques, the company offers transformative treatments that can lead to long-term patient benefits, thus creating a strong market demand for its innovative solutions.
What is the highest forecasted price for BLUE bluebird bio, Inc.?
The highest price target for BLUE is $8.00 from Gena Wang at Barclays, which represents a 61.0% increase from the current price of $4.97.
What is the lowest forecasted price for BLUE bluebird bio, Inc.?
The lowest price target for BLUE is $8.00 from Gena Wang at Barclays, which represents a 61.0% increase from the current price of $4.97.
What is the overall BLUE consensus from analysts for bluebird bio, Inc.?
The overall analyst consensus for BLUE is neutral. Out of 24 Wall Street analysts, 1 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $8.00.
How accurate are BLUE stock price projections?
Stock price projections, including those for bluebird bio, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 10, 2026 2:12 AM UTC